Literature DB >> 21060030

Primary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-cell collection.

Qaiser Bashir1, Lauren A Langford, Simrit Parmar, Richard E Champlin, Muzaffar H Qazilbash.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21060030     DOI： 10.1200/JCO.2010.31.4161

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis.

Authors:  B Dhakal; A D'Souza; C Arce-Lara; M Pasquini; W Saber; F Falvo; J Esselman; K Zellner; T Fenske; P N Hari; M Hamadani
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

Review 2.  New developments in diagnosis, risk assessment and management in systemic amyloidosis.

Authors:  Iuliana Vaxman; Angela Dispenzieri; Eli Muchtar; Morie Gertz
Journal:  Blood Rev       Date:  2019-11-02       Impact factor: 8.250

3.  An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis.

Authors:  Talha Badar; Binod Dhakal; Aniko Szabo; Anand Padmanabhan; Bryon D Johnson; Sarah Heidtke; Jean Esselmann; Saurabh Chhabra; Mehdi Hamadani; Parameswaran Hari; Anita D'Souza
Journal:  J Clin Apher       Date:  2019-09-30       Impact factor: 2.821

Review 4.  Comprehensive Review of AL amyloidosis: some practical recommendations.

Authors:  Rama Al Hamed; Abdul Hamid Bazarbachi; Ali Bazarbachi; Florent Malard; Jean-Luc Harousseau; Mohamad Mohty
Journal:  Blood Cancer J       Date:  2021-05-18       Impact factor: 11.037
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.